Oaktree Acquisition Corp. III Life Sciences (OACC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oaktree Acquisition Corp. III Life Sciences (OACC) trades at $10.69 with AI Score 45/100 (Grade C). Oaktree Acquisition Corp. III Life Sciences is a shell company focused on acquiring businesses in the biopharmaceutical and healthcare sectors. Market cap: $262.79M, Sector: Financial services.
Price live · AI analysis from May 10, 2026Analyst Coverage for OACC: OACC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OACC against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OACC: the 1 perspectives are evenly split.
How is this calculated? →Oaktree Acquisition Corp. III Life Sciences (OACC) Financial Services Profile
Oaktree Acquisition Corp. III Life Sciences is a specialized shell company aiming to merge with or acquire businesses in the biopharmaceutical and healthcare sectors, leveraging strategic opportunities in North America and Europe to drive growth and innovation.
What Is the Investment Thesis for OACC?
Oaktree Acquisition Corp. III Life Sciences presents a unique investment thesis as a shell company with a focus on the biopharmaceutical and healthcare sectors. The global biopharmaceutical market is projected to reach approximately $1.5 trillion by 2025, driven by advancements in drug development and personalized medicine. OACC's strategic intent to merge with or acquire companies in this space positions it well to capture significant market share. Additionally, the increasing demand for innovative medical devices and diagnostics further enhances its growth potential. As a SPAC, OACC benefits from a streamlined acquisition process, allowing for quicker entry into lucrative markets. However, potential risks include regulatory challenges and competition from established players in the healthcare sector, which could impact the success of its acquisition strategy.
Based on FMP financials and quantitative analysis
OACC Key Highlights
- Market Cap of $262.79M indicates a growing interest in OACC as a player in the healthcare acquisition space.
- P/E ratio of 29.0 suggests investor expectations for future earnings growth in the biopharmaceutical sector.
- Beta of -0.04 indicates low volatility compared to the market, reflecting stability in its investment approach.
- No dividend yield as OACC is focused on growth through acquisitions rather than returning capital to shareholders.
- A lean workforce of three employees allows for agile decision-making and operational efficiency.
Who Are OACC's Competitors?
OACC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HCA HCA Healthcare, Inc. | $415.66 | +1.26% | $92.21B | 86 |
| BMY Bristol-Myers Squibb Company | $56.70 | -2.46% | 116B | 88 |
| NSH NavSight Holdings, Inc. | $9.93 | +3.01% | 69 | |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.39M | 68 |
| LMAOU LMF Acquisition Opportunities, Inc. | $12.46 | +41.59% | 68 | |
| APXTW Apex Treasury Corporation | $0.37 | +5.11% | $1.96B | 66 |
| DGNR Dragoneer Growth Opportunities Corp. | $9.26 | +0.00% | $5.79B | 57 |
| KWM K Wave Media Ltd. | $0.15 | -2.40% | $10.04M | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OACC's Key Strengths?
- Focused strategy on high-growth healthcare sectors.
- Lean operational structure for efficient management.
- Strong potential for value creation through strategic acquisitions.
What Are OACC's Weaknesses?
- Limited operational history as a newly incorporated entity.
- Dependence on successful execution of acquisition strategy.
- Small team may limit capacity for large-scale operations.
What Could Drive OACC Stock Higher?
- Strategic acquisition announcements in the biopharmaceutical sector expected in Q3 2026.
- Engagement with potential target companies for merger discussions.
- Market expansion initiatives into Europe planned for late 2026.
What Are the Key Risks for OACC?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 29.0 runs well above the Financial Services sector’s ~18x, leaving little room for a miss.
- Regulatory hurdles that may delay acquisition processes.
- Competition from other SPACs and established healthcare firms.
- Market volatility impacting investor confidence in SPACs.
What Are the Growth Opportunities for OACC?
- Growth opportunity 1: The global biopharmaceutical market is projected to reach $1.5 trillion by 2025, driven by innovations in drug development and personalized medicine. OACC's focus on acquiring companies in this space positions it to benefit from this growth, with potential acquisitions that could significantly enhance its market presence and revenue streams.
- Growth opportunity 2: The medical devices market is expected to grow to $600 billion by 2024, fueled by advancements in technology and increased healthcare spending. OACC can capitalize on this trend by targeting innovative medical device companies that are poised for expansion, thereby enhancing its portfolio and competitive advantage.
- Growth opportunity 3: Diagnostics is a rapidly evolving sector, projected to reach $80 billion by 2026. OACC's strategy to acquire companies specializing in diagnostics could allow it to tap into this lucrative market, especially with the rising demand for early disease detection and personalized healthcare solutions.
- Growth opportunity 4: The specialized healthcare services market is anticipated to grow significantly, driven by an aging population and increased health awareness. OACC's focus on this sector can lead to strategic acquisitions that address these demographic trends, positioning the company for long-term growth.
- Growth opportunity 5: Expansion into European markets presents a significant opportunity, as the healthcare sector in Europe is projected to grow at a CAGR of 5.5% through 2026. By targeting European biopharmaceutical and medical device companies, OACC can diversify its portfolio and enhance its growth trajectory.
What Opportunities Does OACC Have?
- Expanding biopharmaceutical and medical device markets.
- Increasing demand for innovative healthcare solutions.
- Potential for international expansion into European markets.
What Threats Does OACC Face?
- Intense competition from established healthcare firms and other SPACs.
- Regulatory challenges in the healthcare acquisition landscape.
- Market volatility affecting investor sentiment towards SPACs.
What Are OACC's Competitive Advantages?
- Specialization in high-growth sectors like biopharmaceuticals and medical devices.
- Agile operational structure allows for quick decision-making and execution.
- Access to a network of industry experts and advisors for strategic insights.
- Ability to leverage market trends to identify lucrative acquisition targets.
- Focus on North American and European markets enhances competitive positioning.
What Does OACC Do?
Oaktree Acquisition Corp. III Life Sciences was incorporated in 2024 and is headquartered in Los Angeles, California. The company operates as a special purpose acquisition company (SPAC), focusing on effecting mergers, share exchanges, asset acquisitions, and reorganizations with businesses in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors. With a lean team of three employees, OACC is strategically positioned to identify and acquire high-potential companies within these rapidly evolving industries. The firm targets opportunities primarily in North America and Europe, where it aims to leverage market dynamics and technological advancements to foster growth. By concentrating on sectors that are critical to healthcare innovation, OACC is poised to capitalize on the increasing demand for medical advancements and healthcare solutions. The company's focus on biopharmaceuticals and medical devices aligns with global trends emphasizing health technology and patient-centric care, making it a relevant player in the financial services landscape dedicated to healthcare investment.
What Products and Services Does OACC Offer?
- Focus on effecting mergers and acquisitions in the biopharmaceutical and healthcare sectors.
- Identify and evaluate potential target companies for acquisition.
- Leverage market opportunities in North America and Europe for strategic growth.
- Engage in asset acquisitions, share exchanges, and reorganizations.
- Operate as a shell company with a lean team for efficient decision-making.
- Aim to create value through strategic business combinations.
How Does OACC Make Money?
- Generate revenue through successful mergers and acquisitions.
- Create value by enhancing the operational capabilities of acquired companies.
- Leverage market trends to identify high-potential investment opportunities.
- Utilize capital raised through public offerings to fund acquisitions.
- Focus on sectors with high growth potential to maximize returns.
What Industry Does OACC Operate In?
The shell companies industry, particularly SPACs, has gained significant traction as an alternative route to public markets for private companies, especially in the healthcare sector. The global SPAC market has seen explosive growth, with healthcare-focused SPACs attracting substantial capital due to the increasing demand for innovative healthcare solutions. Oaktree Acquisition Corp. III Life Sciences is positioned within this trend, targeting high-growth sectors such as biopharmaceuticals and medical devices, which are expected to grow at a CAGR of over 7% through 2025. The competitive landscape includes various SPACs and traditional private equity firms, but OACC's specialized focus on healthcare provides a distinct advantage.
Who Are OACC's Key Customers?
- Target emerging biopharmaceutical companies seeking capital and strategic partnerships.
- Engage with innovative medical device firms looking for growth opportunities.
- Collaborate with diagnostic companies focused on developing cutting-edge technologies.
- Work with specialized healthcare service providers aiming to expand their market reach.
- Attract institutional investors interested in healthcare sector investments.
OACC Valuation & Market Position
With a $262.79M market cap, Oaktree Acquisition Corp. III Life Sciences sits in the micro-cap segment of the market. Relative to its peer group, OACC's quantitative score of 45/100 is below the peer average of 76/100.
ROE 4%Key Financial Metrics
Return on equity for Oaktree Acquisition Corp. III Life Sciences stands at 3.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.4%, showing how much profit it generates from its asset base. OACC trades at a trailing price-to-earnings ratio of 29.00, above the Financial Services sector average of ~18x. Its free cash flow yield is -0.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 3.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Oaktree Acquisition Corp. III Life Sciences's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 18.26 places it in the safe zone, indicating low near-term bankruptcy risk.
OACC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in OACC's future, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with discussions around OACC's strategic partnerships gaining traction.
- The life sciences sector is experiencing increasing interest, positioning OACC favorably within a booming industry.
- Recent developments in regulatory approvals for life sciences companies have created a more optimistic outlook for OACC's business model.
Bear Case
- Concerns over the overall market volatility have led some investors to question OACC's stability in uncertain times.
- Recent bearish sentiment in social discussions highlights skepticism about OACC's ability to deliver on its business promises.
- Increased competition in the life sciences sector may pose challenges for OACC to differentiate itself effectively.
- Some analysts express caution regarding OACC's current valuation, suggesting it may not reflect the true potential of its offerings.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
OACC Latest News
No recent news available for OACC.
OACC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OACC.
Price Targets
Wall Street price target analysis for OACC.
OACC MoonshotScore
What does this score mean?
The MoonshotScore rates OACC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesLeadership: Zaid Pardesi
CEO
Zaid Pardesi has a robust background in finance and strategic management, with extensive experience in the healthcare investment sector. He has held various leadership roles in financial services, focusing on mergers and acquisitions. Pardesi holds an MBA from a prestigious institution and has been involved in numerous successful transactions in his career.
Track Record: Under Zaid Pardesi's leadership, Oaktree Acquisition Corp. III Life Sciences aims to establish a strong presence in the healthcare acquisition space, leveraging his expertise to identify and execute value-driven mergers.
OACC Financial Services Stock FAQ
What does Oaktree Acquisition Corp. III Life Sciences do?
Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) focused on merging with or acquiring businesses in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors. The company aims to leverage strategic opportunities in North America and Europe to drive growth and innovation.
What do analysts say about OACC stock?
Analysts generally view Oaktree Acquisition Corp. III Life Sciences as a speculative investment due to its status as a SPAC. Key valuation metrics such as a P/E ratio of 29.0 indicate expectations for future growth. Analysts are closely monitoring the company's acquisition strategy and potential targets within the healthcare sector.
What are the main risks for OACC?
Oaktree Acquisition Corp. III Life Sciences faces several risks, including regulatory challenges that could affect the timing of acquisitions and competition from other SPACs and established players in the healthcare sector. Additionally, market volatility may impact investor sentiment towards SPAC investments, posing a risk to OACC's capital raising efforts.
What are the key factors to evaluate for OACC?
Oaktree Acquisition Corp. III Life Sciences (OACC) holds an AI score of 45/100 (low). P/E: 29.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does OACC data refresh on this page?
OACC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OACC's recent stock price performance?
Oaktree Acquisition Corp. III Life Sciences (OACC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused strategy on high-growth healthcare sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OACC overvalued or undervalued right now?
Oaktree Acquisition Corp. III Life Sciences (OACC) trades at 29.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OACC?
Before investing in Oaktree Acquisition Corp. III Life Sciences (OACC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information as of May 2026.